187 GSK Annual Report 2017 Strategic report Governance and remuneration Financial statements Investor information 21.
Other investments 2017 2016 m m At 1 January 985 1,255 Exchange adjustments 64 211 Additions 80 96 Net fair value movements 11 130 Impairment losses 30 24 Disposals 64 683 At 31 December 918 985 Other investments comprise non-current equity investments which are available-for-sale investments recorded at fair value at each balance sheet date.
For investments traded in an active market, the fair value is determined by reference to the relevant stock exchange quoted bid price.
For other investments, the fair value is estimated by management with reference to relevant available information, including the current market value of similar instruments and discounted cash flows of the underlying net assets.
Other investments include listed investments of 535 million 2016 580 million.
The most significant of the investments held at 31 December 2017 was in Theravance Biopharma, Inc. in which the Group holds 17.8% of the common stock.
This investment had a fair value at 31 December 2017 of 199 million 2016 248 million.
The other investments include equity stakes in companies with which GSK has research collaborations and in companies which provide access to biotechnology developments of potential interest.
On disposal of investments, fair value movements are reclassified from equity to the income statement based on average cost for shares acquired at different times.
The impairment losses recorded above have been recognised in the income statement for the year within Other operating income, together with amounts reclassified from the fair value reserve on recognition of the impairments.
These impairments initially result from prolonged or significant declines in the fair value of the equity investments below acquisition cost, subsequent to which any further declines in fair value are immediately taken to the income statement.
The carrying value at 31 December of Other investments which have been impaired is as follows: 2017 2016 m m Original cost 475 515 Cumulative impairments recognised in the income statement 283 314 Subsequent fair value increases 210 282 Carrying value at 31 December 402 483 22.
Other non-current assets 2017 2016 m m Amounts receivable under insurance contracts 648 602 Pension schemes in surplus 538 313 Other receivables 227 284 1,413 1,199 23.
